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Background
Three recent randomised controlled
trials [1–3] in Kenya, South Africa, and
Uganda have confirmed previous obser-
vational studies [4] and ecological experi-
ence [5] and demonstrated beyond rea-
sonable doubt that male circumcision
performed by well-trained medical profes-
sionals reduces the risk of men acquiring
HIV through female-to-male transmission
by approximately 60% [5,6]. Further-
more, results from the Kenyan trial
indicate that the protective effects of
circumcision are sustained for at least
42 mo [7], which suggests that circumci-
sion is likely to provide life-long partial
protection.
Although the evidence from the rando-
mised trials is compelling, the longer-term
population-level impact of introducing or
expanding safe male circumcision services
within comprehensive HIV prevention
programmes remains unknown. Conse-
quently, although some countries with a
high prevalence of HIV have held stake-
holder meetings and are developing poli-
cies on male circumcision for HIV pre-
vention, many have not done so. In
addition, the introduction and/or expan-
sion of male circumcision programmes for
HIV prevention raises a host of ethical,
legal, and human rights issues [8–10].
Furthermore, the introduction/expansion
of these programmes could be hindered by
weak health infrastructures, scarce human
resources for health [11], cultural con-
cerns, political barriers, and financial
constraints. In the face of these challenges,
some decision-makers in sub-Saharan
Africa are asking whether the introduction
or expansion of male circumcision services
for the reduction of HIV incidence will be
cost-effective over the short, medium, and
long term.
Estimating the long-term population
impact and cost-effectiveness of male
circumcision programmes requires math-
ematical modelling approaches. However,
when different modelling approaches use
different baseline assumptions and input
variables, they sometimes produce con-
flicting results. The Joint United Nations
Programme on HIV/AIDS (UNAIDS),
the World Health Organization (WHO),
and the South African Centre for Epide-
miological Modelling and Analysis (SA-
CEMA) recently convened three expert
group meetings in Geneva (2005), Stellen-
bosch (2007), and London (2008) to review
published and unpublished modelling
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Summary Points
N Mathematical models can estimate the population-level impact of male
circumcision on HIV incidence in high HIV prevalence settings, but different
methods, assumptions, and input variables can produce conflicting results.
N UNAIDS/WHO/SACEMA recently convened experts to review the outcomes of
six simulation models on key policy and programmatic decision-making
questions.
N Large benefits of male circumcision among heterosexual men in low male
circumcision, high HIV prevalence settings were found: one HIV infection being
averted for every five to 15 male circumcisions performed, and costs to avert
one HIV infection ranging from US$150 to US$900 using a 10-y time horizon.
N The models predicted that both premature postoperative resumption of sexual
intercourse and behavioural risk compensation, if confined to newly or already
circumcised men and their partners, have only small population level effects on
the anticipated impact of male circumcision service scale-up on HIV incidence.
N Women benefit indirectly from reduced HIV prevalence in circumcised male
partners and male circumcision service scale-up acts synergistically with other
strategies to reduce HIV disease burden.
N The modelling results have informed development of a pragmatic decision-
makers’ programme planning tool.
"Membership of the UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male
Circumcision for HIV Prevention is provided in the Acknowledgments.
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work. Specifically, the expert group meet-
ings assessed the potential population-
level effects of male circumcision on HIV
incidence predicted by these models and
determined the relevance of mathematical
modelling approaches to informed deci-
sion-making about the scale-up of male
circumcision programmes.
The Mathematical Models
At the 2008 meeting, the expert group
reviewed the following mathematical mod-
els for the effects of male circumcision on
HIV incidence and prevalence:
N A deterministic compartmental model
based on scenarios for settings similar
to Botswana and Nyanza Province,
Kenya [12];
N A stochastic simulation model that
included parameters empirically de-
rived from a cohort in Rakai, Uganda
[13];
N A very simple compartmental model
using South African data to estimate
epidemiological parameters and to
construct an aggregate model for sub-
Saharan Africa [14];
N Two deterministic compartmental
models of heterosexual HIV spread
in populations stratified for sex and
risk behaviour [15,16];
N An individual-based micro-simulation
model with formation and dissolution
of heterosexual relationships and HIV
transmission modelled as stochastic
events [17].
To estimate the costs associated with
changes in HIV prevalence and incidence
predicted by each model, the expert group
used data from a cost-effectiveness study
based on the randomised controlled South
African trial [18,19], costing information
from the randomised controlled Kenyan
[20] and Ugandan trials [13], and data
from costing studies conducted in Lesotho
[21], Swaziland [22], and Zambia [23].
Summary properties of these models
(and two additional modelling exercises
published after the third meeting [24,25]),
are shown in Table 1, together with key
results.
The six models considered by the expert
group had been independently applied to
various settings to estimate the overall
impact on HIV incidence of the scale-up
of male circumcision. The models had also
been used to estimate the relative impact of
the scale-up of male circumcision among
different population subgroups, on the
numbers needed to treat, and on cost-
effectiveness. Finally, the models had been
used to investigate the influence of factors
such as declining HIV incidence, potential
changes in risk behaviour, and the effects of
other HIV prevention programmes. Be-
cause observational data on HIV risk and
circumcision status among men who have
sex with men do not suggest a strong
protective effect [26], this population was
not included in any of the models. With one
recently submitted exception [16], the
models had all been published in peer-
reviewed scientific journals with detailed
supplementary material before being con-
sidered by the expert group.
As shown in Table 2, although the
models used different methods, baseline
assumptions, and input variables, their
essential components were similar. For
example, the models’ programmatic, bio-
logical, and behavioural variables general-
ly included age group targets, risk group
targets, speed of service scale-up, final
level of male circumcision coverage
reached, presumed risk of female-to-male
and male-to-female HIV transmission,
HIV acquisition and transmission risk
during postoperative wound healing, and
potential risk compensation [27], such as
less frequent condom use and increased
numbers of sex partners. Modelled out-
comes included impact on HIV incidence
and HIV prevalence, and the number of
male circumcisions required to avert one
HIV infection. A brief summary of the
models and the analyses conducted with
each one is provided in Text S1, and the
presentations made at the last two expert
group meetings are provided in Text S2.
Application of the Models to
Key Questions
Before its third meeting, the expert
group identified eight key questions with
implications for policy and programmatic
decision-making. They then considered the
findings from the models relevant to each of
the questions in turn at the meeting. Not all
of the models addressed all of the topics.
Furthermore, in many cases, the quantita-
tive outputs from the models could not be
directly compared because alternative un-
derlying assumptions had been made and
their results related to different contexts.
For this reason, the expert group did not
attempt to quantify the variation in model
results formally even though each of the
published articles contained an analysis of
the uncertainty in the relevant model’s
projections.
During the discussion of each preselected
topic, a broad qualitative consensus
emerged from the findings of the specific
models being examined, which was agreed
upon by all the members of the expert
group. Indeed, the varied nature of the
models and the independence of the
researchers involved in these modelling
exercises provide support for the generali-
sability of the findings of the expert group.
What Is the Expected Impact on
HIV Incidence of Scaling Up
Male Circumcision
Programmes?
The expected impact of scaling up male
circumcision services depends on several
critical factors including baseline male
circumcision and HIV prevalence; wheth-
er HIV incidence is increasing, stable, or
declining; the time period of model
projections; and the speed of scale-up.
WHO/UNAIDS guidance on pro-
gramme implications [6] states that the
greatest potential public-health impact will
be in settings where HIV is hyperendemic
(HIV prevalence in the general population
exceeds 15%) and is spread predominantly
through heterosexual transmission, and
where a substantial proportion of men
(e.g., greater than 80%) are not circum-
cised. The six models, therefore, focused
on settings that have an epidemic profile
similar to this.
The models predicted that, using a 10-y
time horizon, one new HIV infection
would be averted for every five to 15
men newly circumcised. For the most
successful interventions, where almost all
men are circumcised, HIV incidence
could be reduced by ,30%–50% over
the same period, with prevalence following
this decrease with some delay (Figure 1;
Table 1). Inevitably, the absolute number
of male circumcisions required to avert
one HIV infection increases as HIV
incidence declines over time.
In countries with lower levels of HIV
prevalence and incidence, such as
Uganda, the number of male circumci-
sions required to avert one new infection is
higher (Table 1) [13]. However, on the
basis of its analysis of the model predic-
tions, the expert group agreed that even in
such countries, programmes that focus on
subpopulations with a high HIV preva-
lence and incidence would have substan-
tial impact on HIV incidence. Pro-
grammes that fall into this category
might include, for example, those that
focus on geographic areas of low male
circumcision prevalence or on subgroups
of heterosexual men at higher risk of HIV
exposure. These subgroups include HIV-
negative men in serodiscordant couples
and men more likely to have multiple sex
partners, such as soldiers, truck drivers,
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miners, labour migrants, or patients at-
tending sexually transmitted disease (STD)
clinics. The expert group noted that,
according to a systematic review and
meta-analysis, men at higher risk of STD
benefit from higher levels of protection
when circumcised (adjusted risk ratio
[RR]= 0.29, 95% confidence interval
[CI] 0.20–0.41) [4].
What Is the Overall Impact on
HIV Incidence in Women?
As sexual partners and parents, women
are affected by male circumcision [28,29].
Although an observational study suggested
that circumcision of HIV-positive men
might reduce transmission to HIV-negative
female partners [30], no such direct effect
was observed in a trial that was prematurely
closed for futility [31]. However, among
those couples who resumed sexual activity
soon after circumcision a nonstatistically
significant but nonetheless concerning trend
was found in this trial toward an increased
risk of HIV infection in women assessed
6 mo after their partners’ circumcision.
All six models showed that women, even
if not directly protected, would benefit
indirectly from the introduction or expan-
sion of male circumcision services because
their probability of encountering an HIV-
infected male sexual partner gradually
declines with programme scale-up. In the
models, these indirect benefits increase
over time, taking some years to become
evident (Figure 1). The expert group noted
that these indirect benefits would eventu-
ally reduce the number of women needing
services to prevent mother-to-child HIV
transmission, although the proportion of
people living with HIV who are women
would increase [14].
In addition, the expert group reviewed
empirical data that show that male
circumcision reduces the acquisition of
herpes simplex virus type-2 [32], syphilis,
and chancroid in HIV-negative men
[3,33], and accumulating evidence that
the circumcision of HIV-positive men
provides direct benefit to women by
reducing genital ulcer disease [34], which
may decrease the likelihood of HIV
transmission. In the Ugandan trial, wom-
en who were the sexual partners of
circumcised HIV-negative men had less
genital ulcer disease and bacterial vagino-
sis, and fewer Trichomonas vaginalis infec-
tions than women with uncircumcised
male partners [35]. Although all these
conditions, with the possible exception of
bacterial vaginosis [36], are associated
with an increased risk of female HIV
acquisition, only one of the models
analysed by the expert group explicitly
included this mechanism [17], which was
also not fully represented in another recent
study [37].
Overall, the expert group concluded
that any of these mechanisms for the
reduction in HIV acquisition for women
could enhance the overall impact of male
circumcision and could hasten reductions
of HIV incidence among women.
What Is the Impact of
Circumcising HIV-Positive Men?
WHO/UNAIDS advise against pro-
moting male circumcision for HIV-posi-
tive men, but state that it should not be
Table 2. Range of variables in the different models.
Author All Models
Williams
et al. [14]
Nagelkerke
et al. [12]
Gray
et al. [13]
Hallett
et al. [15]
White
et al. [17]
Alsallaq
et al. [16]
Baseline HIV incidence
(per 100 person-years)
1.2–4.5 2.4 2.2–4.5 1.2 3.2 1.3–3.2 3.9
Baseline HIV prevalence (%) 11–36 20 18–36 11 23 11–25 28.8
Baseline male circumcision
prevalence (%)
0–50 35 10 16 0 0–50 27.5
Reduction of female-to-male
transmission due to
circumcision (%)
30–76 60 40–75 40–70 60 30–76 60
Target age groups 5-y age groups No age structure No age structure 15–49 5-y age groupsa 5-y age groups No age structure
Target risk groups High- versus low-risk
behaviour men
All men All HIV-negative
men
All men High- versus low-risk
behaviour mena
All HIV-negative
men and all men
High- versus low-
risk behaviour men
Time to reach intended
coverage (y)
0–20 5 or 10 Approximately 10 0–10 5 0–20 0–10
Final circumcision prevalence
reached (%)
25–100 100 50–80 25–100 90 50–100 100
Reduction of male-to-female
transmission risk (%)
0–70 0 0–25 40–70 0–30 0–50 0
Proportion of men who resume
sex before wound healing (%)
0–60 N/A N/A N/A 0–40 15–60 N/A
Relative risk of acquiring or
transmitting HIV during wound
healing
Up to 2.3 N/A N/A N/A 0–2 2.3b N/A
Increase in sexual partner
numbers postcircumcision (%)
0–200 0 0 0–100 0 0 0–200
Reduction in condom use (%) 0–100 N/A 0–100 N/A 0–100 in casual
partnerships
0–100 in casual
and sex worker
contacts
N/A
aThese analyses published in [43].
b.6 mo.
N/A, not applicable.
doi:10.1371/journal.pmed.1000109.t002
PLoS Medicine | www.plosmedicine.org 4 September 2009 | Volume 6 | Issue 9 | e1000109
denied unless medically contraindicated
[6]. HIV testing is recommended for all
men seeking male circumcision, but is not
mandatory [6]. The systematic refusal to
circumcise HIV-positive men based on
their HIV status alone may increase
stigma for all uncircumcised men.
The expert group found that one model
predicted that circumcision of HIV-posi-
tive men in the context of capacity
constraints would mean that fewer HIV-
negative men would be circumcised, thus
reducing the population-level impact of a
circumcision programme on HIV inci-
dence over the short term [17]. However,
the model also suggested that under some
circumstances, this negative result may be
partially offset by lower rates of genital
ulcer disease and reduced onward HIV
transmission to female partners [17].
Two models showed that, assuming no
direct effect of circumcision on male-to-
female HIV transmission, premature post-
operative resumption of sex by HIV-
positive men is unlikely to have an adverse
population-level effect on overall HIV
incidence because any increased risk only
applies for a short period of time, a matter
of weeks [15,17]. When the proportion of
HIV-positive men resuming sex early was
set at 60%, one model showed that the
population-level effect on anticipated HIV
incidence remains small [17]. It should be
noted that in the trials, only 4%–20% of
HIV-negative men resumed sex early [1–
3]. Nonetheless, the expert group conclud-
ed that, regardless of serostatus, it is
important to counsel newly circumcised
men and their partners on the potential for
disruption of wound edges if sex is
resumed too soon after surgery.
The proportion of male circumcisions
performed on HIV-positive men will
depend on HIV prevalence and on how
many clinically eligible HIV-positive men
request surgery. This number is influenced
by scale-up strategies (e.g., there is a
higher HIV prevalence in STD clinics),
the perception of circumcision in the
community (e.g., whether it is perceived
as a marker of HIV-negative status or as a
marker of higher risk), and messages given
to men testing positive or declining HIV
testing. Notably, one of the models
indicates that good uptake among men
with the highest risk of HIV exposure
could amplify the impact of circumcision
programmes [15], even though focusing
programmes on such subgroups will likely
lead to more men who are already infected
being circumcised.
What Is the Effect of Risk
Compensation?
As observed with antiretroviral treat-
ment, a decrease in perceived risk can result
in an increase in sexual risk-taking behav-
iour, a phenomenon termed ‘‘risk compen-
sation’’ [27,38,39]. The randomised trials
of male circumcision [1,3,40] and an
observational study [41] found minimal or
no behavioural risk compensation among
recently circumcised men, although inten-
sive health education during the trials
might have mitigated risk compensation.
The models showed that if risk compen-
sation is confined to newly or already
circumcised men and their partners, it has
only a small effect on the projected
population-level impact of male circumci-
sion on HIV incidence [15–17]. At high
levels of risk compensation (e.g., no male or
female condom use), women who partner
with circumcised men believing them to be
HIV-negative may be placed at increased
individual risk despite lower HIV incidence
in the whole population [15].
Furthermore, the models suggested that
the beneficial impact of male circumcision
for both men and women would be
substantially reduced if risk behaviours
increase across the entire adult population,
including among uncircumcised men and
their partners. In light of these findings,
the expert group agreed that there is a
clear need for intensive social change
communication campaigns, aimed at the
whole population, to prevent increases in
risk behaviours.
How Do the Effects Vary by Age
Group Circumcised?
It is clear that a scale-up of male
circumcision that prioritises the treatment
of subgroups of heterosexual men at the
highest risk of HIV exposure will have the
most rapid initial impact. These subgroups
vary by country but include seronegative
men in discordant couples identified
Figure 1. Reductions in HIV incidence by coverage level. This figure shows model estimates for the reduction in HIV incidence 10 y after the
programme begins, among circumcised men, women, uncircumcised men, and the population overall, at varying levels of circumcision uptake (from
a baseline of 0%). The model [15] is a deterministic compartmental simulation of the heterosexual spread of HIV in a sex- and sexual-activity stratified
population, parameterised for Southern and Eastern African populations. The model assumes that there is a 60% reduction in female-to-male
transmission for circumcised men, that there is no direct reduction in male-to-female transmission from circumcised men, and that 5%, 20%, 35%,
50%, 70%, and 90% of men are circumcised within 10 y of the intervention being scaled-up. Note: Since the fraction of men circumcised increases
over time, the weighted-average of reductions in incidence in these demographic groups at year 10 is not expected to equal the reduction in
incidence in the whole population over the first 10 y of the intervention.
doi:10.1371/journal.pmed.1000109.g001
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during couple counselling and testing,
STD clinic attendees, and adult males
15–34 y old. In many settings HIV
incidence is highest among 25- to 34-y-
old men [42] rather than 15- to 24-y-olds.
Because changes may occur over time,
HIV incidence monitoring in relevant
subpopulations is essential to ensure that
priority groups continue to be accurately
identified.
The models indicated that circumcising
men who have not started sexual activity
leads to the greatest population-level
benefit in the long term, whereas circum-
cising 25- to 34-y olds has the biggest
benefit over the following 10 to 20 y;
circumcising 50-y-old men has little effect
on HIV incidence [17,43]. In the context
of parents and guardians deciding to
circumcise their sons [9] as neonates
rather than when they are older, since
the procedure is simpler, cheaper, and
incurs fewer adverse events, the models
show that reductions in population inci-
dence would probably take 20 to 25 y to
become evident, other factors being equal.
Of course, circumcising both adult males
and neonates would maximise the short-
and long-term impact of circumcision on
HIV incidence. But, if a fully effective
HIV vaccine for adults is widely accessible
by 2025 or high levels of treatment uptake
are achieved [44], some neonatal circum-
cision performed now solely for the
purpose of HIV prevention would have
been unnecessary and thus the projections
of cost-effectiveness of this strategy would
be exaggerated.
How Do the Effects Vary with
Speed of Service Scale-up?
All the models showed that rapid
expansion of male circumcision coverage
will result in earlier and larger effects on
HIV incidence (Figure 1), assuming that
safety standards and the quality of coun-
selling and postoperative care are main-
tained. The models showed that whether
scale-up rates are constant, faster initially
then slowing, or slower initially with
subsequent acceleration, they can still
achieve a specified goal by the target date.
However, studies in Lesotho, Swaziland,
and Zambia found that a faster initial
scale-up would avert between 13.7% and
16.1% more infections by 2015 compared
to a linear scale-up, whereas a slower
initial scale-up would result in 219.7% to
214.5% fewer infections averted, assum-
ing a target coverage in each country of
around 50% by 2015 [45]. Thus, the
expert group concluded from both the
models and empirical data that rapid
initial scale-up accrues direct and indirect
effects earlier and is considerably more
cost-effective, with fewer circumcisions
required to avert one infection and more
HIV infections averted at lower cost per
infection averted over time.
How Does Scale-up of Other
Prevention Initiatives at the
Same Time Affect the Impact of
Male Circumcision Scale-up?
The introduction or expansion of male
circumcision services will occur in settings
where behavioural prevention pro-
grammes (e.g., campaigns to increase male
and female condom use or to reduce
numbers of sexual partners) and biomed-
ical measures (e.g., antiretroviral treat-
ment) may be reducing sexual HIV
transmission. Unlike other HIV preven-
tion strategies that depend on user-adher-
ence, male circumcision, once performed,
is likely to provide lifelong partial protec-
tion against HIV, on the basis of the
available evidence. Furthermore, the
scale-up of male circumcision to reduce
HIV incidence provides an opportunity to
enhance other prevention strategies such
as counselling to reduce risky behaviours,
to increase correct and consistent male
and female condom use, and to encourage
knowledge of HIV serostatus.
All the models showed that male
circumcision would not, in isolation, have
sufficient impact to stop the HIV epidemic
(Table 1). However, one model showed
that substantial synergies are likely to be
achieved by combining approaches [15]
with the greatest impact generated when
circumcision is scaled up in parallel with
an intensified focus on reducing sexual risk
behaviour. Importantly, the expert group
agreed that increasing prevention choices
for people while treatment access is
expanding could potentially speed the
decline of the epidemic.
What Are the Discounted
Savings?
The estimated costs per adult male
circumcision are between $30 and $60
[45] depending on the programme setting,
with neonatal circumcision costing about
one-third this amount. The models esti-
mate costs per infection averted of be-
tween $150 and $900 in high HIV
prevalence settings over a 10-y time
horizon, and $100 to $400 when including
infections averted to 20 y. All the models
indirectly confirmed that the most favour-
able cost-effectiveness ratios will be seen
where HIV incidence is highest. By
comparison, estimates of discounted life-
time treatment costs typically exceed
$7,000 per HIV infection if only first-line
treatment is provided, and twice as much
if second-line treatment is available [46].
This estimate assumes first line antiretro-
viral treatment costs of $300 per patient
per year rising to $500 by 2015, laboratory
and service delivery costs of $300 per
patient per year, survival of 85% in the
first year after treatment initiation and
95% in subsequent years, and 3% discount
rate. Thus, circumcising sexually active
males of any age is likely to be cost saving
[17,18].
From Models to Decision
Making
To assist countries in scaling up safe,
voluntary male circumcision services,
WHO, UNAIDS, and partners have
produced extensive guidance and several
useful tools. For example, they have
produced human rights guidance, a situ-
ational analysis toolkit, a communications
framework, a surgical manual and training
modules, a legal and regulatory self-
assessment tool, and a monitoring and
evaluation tool.
Importantly, the Futures Institute in
collaboration with UNAIDS and the
Health Policy Initiative has produced a
pragmatic, decision-makers’ programme
planning tool [47] that helps analysts and
decision-makers understand the costs and
impacts of policy options. This tool
calculates the cost of male circumcision
services by delivery mode on the basis of
clinical guidelines and locally derived
inputs for staff time and salaries, supplies,
equipment, and shared facility and staff
costs. It allows decision-makers to make
programmatic choices of the intended
target population by age (newborn, ado-
lescent, adult) and risk, while varying
service delivery modes and ancillary ser-
vices, scale-up rates, and coverage goals.
The tool estimates HIV incidence, HIV
prevalence, AIDS deaths, overall costs,
and net cost per HIV infection averted as
a function of numbers of male circumci-
sions performed for each service delivery
and coverage timeframe option.
The expert group confirmed that this
simple, user-friendly tool produces results
consistent with the academic mathemati-
cal models that they considered. Because
academic models cannot be parameterized
for every setting and cannot explore every
possible type of intervention, the published
results from modelling studies cannot be
directly relevant to all settings. However,
by using the models to refine and validate
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a user-friendly tool that can be deployed
locally, decision-makers can indirectly
access the main findings from academic
modelling studies.
Why was it important to use modelling
studies to refine a tool to be used by
decision-makers to design tailored local and
national programmes for the scale-up of
male circumcision services? Rapid scale-up
of male circumcision services in high HIV
prevalence settings in sub-Saharan Africa
will require substantial funding and many
skilled personnel in the short term [19]. It is
critical that unintended consequences of
scale-up be monitored and rectified; that
additional funding is provided; that the new
services strengthen existing surgical, sexual,
and reproductive health programmes; and
that this biomedical addition to combina-
tion HIV prevention acts synergistically
with other strategies to stimulate and
maintain HIV incidence declines. Thus,
mathematical modelling by itself is impor-
tant because it shows the potential for
substantial reductions in HIV transmission
through the introduction or expansion of
male circumcision services. But more
importantly, the decision-makers’ pro-
gramme planning tool, which is informed
by the modelling consensus presented here,
shows what programmes for the scale-up of
male circumcision can achieve in specific
settings, over what time frame, and at what
cost. Finally, provided it is updated with
coverage and cost figures as programmes
scale up, the tool can also be used to
monitor progress and optimize strategies.
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